Omnicell, Inc. $OMCL Shares Bought by Empowered Funds LLC

Empowered Funds LLC grew its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 4,229.9% during the 1st quarter, HoldingsChannel.com reports. The firm owned 262,043 shares of the company’s stock after buying an additional 255,991 shares during the quarter. Empowered Funds LLC’s holdings in Omnicell were worth $8,747,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in OMCL. Dimensional Fund Advisors LP boosted its position in shares of Omnicell by 6.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock valued at $81,791,000 after purchasing an additional 137,834 shares during the period. Wellington Management Group LLP increased its position in Omnicell by 156.4% during the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after buying an additional 1,265,818 shares during the period. Lazard Asset Management LLC increased its position in Omnicell by 3.8% during the second quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock worth $50,225,000 after buying an additional 62,733 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its stake in Omnicell by 2.0% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock valued at $47,095,000 after buying an additional 27,497 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Omnicell by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 1,127,583 shares of the company’s stock valued at $51,088,000 after buying an additional 11,424 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Analyst Ratings Changes

OMCL has been the topic of a number of research reports. Piper Sandler restated an “overweight” rating and set a $45.00 target price (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. KeyCorp reduced their price target on shares of Omnicell from $70.00 to $65.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Wells Fargo & Company decreased their price target on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Weiss Ratings restated a “hold (c-)” rating on shares of Omnicell in a research note on Tuesday, August 4th. Finally, Craig Hallum reiterated a “buy” rating and set a $55.00 target price on shares of Omnicell in a research note on Wednesday, April 29th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $57.86.

Omnicell Stock Down 0.9%

Shares of Omnicell stock opened at $37.30 on Friday. The company has a market cap of $1.70 billion, a P/E ratio of 44.41, a PEG ratio of 1.02 and a beta of 0.98. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. Omnicell, Inc. has a one year low of $29.06 and a one year high of $55.00. The firm has a fifty day moving average of $40.72 and a two-hundred day moving average of $40.15.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.47 by $0.47. The company had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The business’s revenue was up 7.4% on a year-over-year basis. During the same quarter last year, the business earned $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, analysts forecast that Omnicell, Inc. will post 1.3 earnings per share for the current year.

Insider Transactions at Omnicell

In other news, EVP Nnamdi Njoku sold 3,090 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the transaction, the executive vice president directly owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. This represents a 1.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $217,180.50. Following the completion of the sale, the executive vice president directly owned 112,783 shares of the company’s stock, valued at $4,874,481.26. This represents a 4.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is owned by company insiders.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.